Dr. Roger D. Dansey is Chief Medical Officer of Seattle Genetics.
He was previously the senior vice president of Global Clinical Development in Oncology at Merck Research Laboratories. At Merck, Dr. Dansey was instrumental in the development and approval of pembrolizumab (Keytruda), an anti-PD-1 checkpoint immunotherapy. His current work is exploring biomarkers and how we can determine which treatments individual patients would benefit from most.
Dr. Dansey is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.
We are striving to offer treatments to patients that are most likely to benefit. That’s a challenge in a disease as incredibly complex as cancer, but it’s a challenge that we must meet head-on if we’re to continue making a difference in the lives of those impacted by this disease.
Let's spread the word about Immunotherapy! Click to share this page with your community.